Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diazepam + gabapentin is a combination of two pharmaceutical drugs, each with distinct mechanisms of action. Diazepam is a long-acting benzodiazepine that acts as a positive allosteric modulator at the gamma-aminobutyric acid type A (GABA-A) receptor, enhancing the inhibitory effects of GABA in the central nervous system. It is primarily used for anxiety disorders, muscle spasms, alcohol withdrawal symptoms, and as an adjunct in certain seizure disorders[6][8]. Gabapentin is an anticonvulsant and structural analogue of GABA but does not bind directly to GABA receptors; instead, it binds to the alpha-2-delta subunit of voltage-gated calcium channels in the CNS, reducing excitatory neurotransmitter release. Gabapentin is mainly indicated for partial seizures and neuropathic pain[4][10]. The combination may be used off-label under special circumstances where both indications overlap (such as complex seizure management or severe neuropathic pain with comorbid anxiety), but co-administration increases risks such as CNS depression (drowsiness, dizziness, confusion) and should be closely monitored[1][3][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diazepam + gabapentin.